Cebon, J. S., Gore, M., Thompson, J. F., Davis, I. D., McArthur, G. A., Walpole, E., Smithers, M., Cerundolo, V., Dunbar, P. R., MacGregor, D., Fisher, C., Millward, M., Nathan, P., Findlay, M. P. N., Hersey, P., Evans, T. R. J., Ottensmeier, C. H., Marsden, J., Dalgleish, A. G., Corrie, P. G., Maria, M., Brimble, M., Williams, G., Winkler, S., Jackson, H. M., Endo-Munoz, L., Tutuka, C. S. A., Venhaus, R., Old, L. J., Haack, D., Maraskovsky, E., Behren, A., & Chen, W. (2020). results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. Journal for immunotherapy of cancer, 8(1), . http://access.bl.uk/ark:/81055/vdc_100127569687.0x000033